Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial

 
• By Joseph Haas

Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.

HIV prep
Gilead is working to add a twice-annual injectable option for HIV PrEP • Source: Shutterstock

More from Clinical Trials

More from R&D